Small-molecule integrin inhibitors are catching the attention of pharmaceutical firms, with fibrosis joining gut dysfunction as a key indication for integrin-based interventions.

中文翻译：

---

整合素靶向疗法分支

小分子整联蛋白抑制剂引起了制药公司的关注，纤维化导致肠道功能障碍是基于整联蛋白的干预措施的关键指标。